BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC

Friday, November 2, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

- Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC

Presentations at SITC: Friday 9 November, 12:45 – 2:15 p.m. and 6:30 – 8 p.m. EST, Hall E

 

A Phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Analysis of the first stage

  • Matthew Krebs, PhD et al
  • Category: 33rd Annual Meeting Late-Breaking Abstracts
  • Presentation number: P715

Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma

  • Robert Holt, PhD, et al
  • Category: Biomarkers and Immune Monitoring
  • Presentation number: P115



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store